---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-013441"
form_type: "8-K"
ticker: "CMPS"
cik: "0001816590"
company_name: "COMPASS Pathways plc"
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:55:59.972245+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# COMPASS Pathways reports Q1 2022 net loss of $21.2M; cash $243.7M; FDA end-of-phase II meeting held

## Summary
- Net loss $21.2M ($0.50/sh) vs $12.7M ($0.35) in Q1 2021; R&D expenses $15.4M (up from $6.9M).
- Cash and cash equivalents $243.7M as of March 31, 2022, down from $273.2M at Dec 31, 2021.
- End-of-phase II meeting with FDA completed; finalizing Phase III design for TRD program targeting H2 2022.
- Awarded Innovation Passport under UK MHRA ILAP for COMP360 psilocybin therapy.
- Phase II trial in PTSD ongoing; collaboration with King's College London and NHS for mental health research.

## SEC filing metadata
- accession: 0001628280-22-013441
- form_type: 8-K
- ticker: CMPS
- cik: 0001816590
- company_name: COMPASS Pathways plc
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816590/000162828022013441/0001628280-22-013441-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816590/000162828022013441/cmps-20220510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-013441
- JSON: https://secwatch.observer/filing/0001628280-22-013441.json
- Plain text: https://secwatch.observer/filing/0001628280-22-013441.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.